Related Experiment Video

Updated: Apr 3, 2026

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

2.9K

Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging

Mohamed Bouattour1, Audrey Payancé1, Johanna Wassermann1

  • 1Mohamed Bouattour, Audrey Payancé, Department of Hepatology, Beaujon University Hospital (AP-HP - Paris 7 Diderot), 92110 Clichy, France.

World Journal of Hepatology
|September 19, 2015
PubMed

Insights

Sorafenib offers clinical benefit for advanced hepatocellular carcinoma. Identifying biomarkers to predict patient response to sorafenib is crucial for optimizing treatment strategies.

Area of Science:

  • Hepatobiliary oncology
  • Pharmacogenomics
  • Translational medicine

Background:

  • Sorafenib is a validated treatment for advanced hepatocellular carcinoma (HCC).
  • Despite initial enthusiasm, subsequent therapies have not surpassed sorafenib's efficacy.
  • Research is shifting towards optimizing sorafenib treatment and patient care.

Purpose of the Study:

  • To explore the identification of prognostic and predictive biomarkers for sorafenib in advanced HCC.
  • To address the challenge of personalizing sorafenib therapy in HCC management.

Main Methods:

  • Investigating potential biomarkers associated with sorafenib response in HCC patients.
  • Analyzing clinical data to identify factors predicting treatment outcomes.

Main Results:

  • The identification of reliable biomarkers for sorafenib remains a significant challenge in advanced HCC.
  • Further research is needed to overcome current therapeutic limitations.

Conclusions:

  • Biomarker discovery is essential for optimizing sorafenib treatment in advanced HCC.
  • Successful biomarker identification could personalize therapy and improve patient outcomes, mirroring successes in other cancers.
Keywords:
Antiangiogenic therapiesFunctional imagingHepatocellular carcinomaPredictive biomarkersPrognosis biomarkersSorafenib

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257